Should I buy or sell REGENXBIO stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RGNX shares. View RGNX analyst ratings or view top-rated stocks .

What is REGENXBIO's stock price target for 2024?

8 brokers have issued twelve-month price objectives for REGENXBIO's shares. Their RGNX share price targets range from $14.00 to $55.00. On average, they anticipate the company's stock price to reach $31.13 in the next twelve months. This suggests a possible upside of 59.5% from the stock's current price. View analysts price targets for RGNX or view top-rated stocks among Wall Street analysts .

How have RGNX shares performed in 2023?

REGENXBIO's stock was trading at $22.68 at the start of the year. Since then, RGNX shares have decreased by 13.9% and is now trading at $19.52. View the best growth stocks for 2023 here .

When is REGENXBIO's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our RGNX earnings forecast .

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) posted its earnings results on Wednesday, November, 8th. The biotechnology company reported ($1.41) EPS for the quarter, topping analysts' consensus estimates of ($1.44) by $0.03. The biotechnology company had revenue of $28.90 million for the quarter, compared to analyst estimates of $26.14 million. REGENXBIO had a negative trailing twelve-month return on equity of 59.54% and a negative net margin of 262.18%. The firm's revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter last year, the company earned ($1.75) EPS.

What ETFs hold REGENXBIO's stock?

ETFs with the largest weight of REGENXBIO (NASDAQ:RGNX) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM) . Virtus LifeSci Biotech Clinical Trials ETF (BBC) .

What is Ken Mills' approval rating as REGENXBIO's CEO?

3 employees have rated REGENXBIO Chief Executive Officer Ken Mills on Glassdoor.com . Ken Mills has an approval rating of 68% among the company's employees.

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV) , Micron Technology (MU) , NVIDIA (NVDA) , Voyager Therapeutics (VYGR) , Amarin (AMRN) , CRISPR Therapeutics (CRSP) , Pfizer (PFE) , QUALCOMM (QCOM) , Gilead Sciences (GILD) and Block (SQ) .

Who are REGENXBIO's major shareholders?

REGENXBIO's stock is owned by many different retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (8.33%), Redmile Group LLC (5.85%), Jacobs Levy Equity Management Inc. (1.28%), Northern Trust Corp (0.98%), Bank of New York Mellon Corp (0.82%) and Charles Schwab Investment Management Inc. (0.74%). Insiders that own company stock include Allan M Fox , Curran Simpson, Kenneth T Mills , Kenneth T Mills , Patrick J Christmas, Steve Pakola , Vittal Vasista and WR Stephens, Iii 2012 Trust. View institutional ownership trends .

How do I buy shares of REGENXBIO?

Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Positive News SentimentPositive News

REGENXBIO Stock Price, News & Analysis (NASDAQ:RGNX)

$19.55

+0.03 (+0.15%)

(As of 02:50 PM ET)

Compare

Today's Range: $19.09
▼
$19.82
50-Day Range: $12.89
▼
$20.03
52-Week Range: $12.82
▼
$25.54

Volume: 136,035 shs
Average Volume: 407,896 shs
Market Capitalization: $860.00 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $31.13

REGENXBIO MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 59.5% Upside
$31.13 Price Target
Short Interest: Bearish
10.20% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.82
Upright™ Environmental Score
News Sentiment: 1.67
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.98) to ($2.45) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

290th out of 949 stocks

Biological Products, Except Diagnostic Industry

46th out of 163 stocks

3.3

Analyst's Opinion

Consensus Rating
REGENXBIO has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $31.13, REGENXBIO has a forecasted upside of 59.5% from its current price of $19.52.
Amount of Analyst Coverage
REGENXBIO has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
10.20% of the float of REGENXBIO has been sold short.
Short Interest Ratio / Days to Cover
REGENXBIO has a short interest ratio ("days to cover") of 9.2.
Change versus previous month
Short interest in REGENXBIO has recently decreased by 1.93%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
REGENXBIO does not currently pay a dividend.
Dividend Growth
REGENXBIO does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
REGENXBIO has received a 71.89% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for REGENXBIO is -0.82.

3.1

News and Social Media Coverage

News Sentiment
REGENXBIO has a news sentiment score of 1.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for REGENXBIO this week, compared to 2 articles on an average week.
MarketBeat Follows
3 people have added REGENXBIO to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, REGENXBIO insiders have not sold or bought any company stock.
Percentage Held by Insiders
12.70% of the stock of REGENXBIO is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
88.80% of the stock of REGENXBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for REGENXBIO are expected to grow in the coming year, from ($4.98) to ($2.45) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of REGENXBIO is -3.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of REGENXBIO is -3.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
REGENXBIO has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About REGENXBIO Stock (NASDAQ:RGNX)

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. In addition, it also develops RGX-121 for the treatment of mucopolysaccharidosis type II and is in Phase III clinical trial; RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. Further, the company also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

RGNX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RGNX Stock News Headlines

November 29, 2023 | finance.yahoo.com

REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial

November 16, 2023 | finance.yahoo.com

Wall Street Analysts Believe Regenxbio (RGNX) Could Rally 95.61%: Here's is How to Trade

December 1, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.

November 12, 2023 | finance.yahoo.com

REGENXBIO (NASDAQ:RGNX) adds US$111m to market cap in the past 7 days, though investors from five years ago are still down 72%

November 9, 2023 | finance.yahoo.com

REGENXBIO Inc. (NASDAQ:RGNX) Q3 2023 Earnings Call Transcript

November 9, 2023 | bizjournals.com

Rockville biotech RegenxBio to cut workforce by 15%, pursue strategic alternatives for several programs

November 9, 2023 | finanznachrichten.de

REGENXBIO Inc.: REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results

November 8, 2023 | marketwatch.com

Regenxbio Cutting 15% of Staff, Exploring Strategic Alternatives

December 1, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 8, 2023 | finance.yahoo.com

REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results

November 7, 2023 | benzinga.com

Earnings Preview For Regenxbio

November 3, 2023 | finance.yahoo.com

REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

November 2, 2023 | msn.com

Regenxbio: Biotech To Watch With 2 Possible Accelerated Approval Pathways

November 2, 2023 | msn.com

Stifel Initiates Coverage of Regenxbio (RGNX) with Buy Recommendation

November 1, 2023 | msn.com

Stifel starts Regenxbio at buy; cites broad platform, deep portfolio

November 1, 2023 | finance.yahoo.com

REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational Highlights

October 30, 2023 | finance.yahoo.com

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting

October 25, 2023 | seekingalpha.com

Regenxbio: Promising Yet Risky Therapeutic Horizon

October 6, 2023 | msn.com

Wedbush Reiterates Regenxbio (RGNX) Neutral Recommendation

October 5, 2023 | markets.businessinsider.com

Promising DMD Gene Therapy Results Bolster Buy Rating for RegenXBio: An Analysis of Brian Skorney’s Recommendation

October 5, 2023 | finance.yahoo.com

REGENXBIO to Participate in the Jefferies CNS/Neuro Summit

October 4, 2023 | markets.businessinsider.com

Hold Rating on REGENXBIO Amid Promising Yet Preliminary Duchenne Trial Results

October 4, 2023 | seekingalpha.com

Regenxbio up after hours on early-stage Duchenne candidate

October 3, 2023 | seekingalpha.com

OMEE, TNDM and RGNX are among after hour movers

October 3, 2023 | finance.yahoo.com

REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE™ Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society

September 26, 2023 | finance.yahoo.com

REGENXBIO Announces Presentations at the 28th Annual Congress of the World Muscle Society

September 22, 2023 | finance.yahoo.com

We're Keeping An Eye On REGENXBIO's (NASDAQ:RGNX) Cash Burn Rate

See More Headlines

Receive RGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2023
Today: 12/01/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RGNX
CUSIP: N/A
CIK: 1590877
Web: www.regenxbio.com
Phone: (240) 552-8181
Fax: N/A
Employees: 401
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $31.13
High Stock Price Target: $55.00
Low Stock Price Target: $14.00
Potential Upside/Downside: +58.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.98)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-280,320,000.00
Net Margins: -262.18%
Pretax Margin: -262.23%
Return on Equity: -59.54%
Return on Assets: -35.97%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.87
Quick Ratio: 2.87

Sales & Book Value

Annual Sales: $112.72 million
Price / Sales: 7.68
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.25 per share
Price / Book: 2.39

Miscellaneous

Outstanding Shares: 43,990,000
Free Float: 38,405,000
Market Cap: $865.72 million
Optionable: Optionable
Beta: 1.12

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Kenneth T. Mills (Age 48)
President, CEO & Director
Comp: $1.02M
Mr. Vittal K. Vasista (Age 55)
Executive VP & CFO
Comp: $671.41k
Mr. Curran M. Simpson M.S. (Age 61)
Executive VP & COO
Comp: $677.7k
Dr. Olivier Danos Ph.D. (Age 65)
Executive VP & Chief Scientific Officer
Comp: $728.06k
Dr. Stephen Pakola M.D. (Age 54)
Executive VP & Chief Medical Officer
Comp: $673.76k
Mr. Patrick J. Christmas II (Age 52)
J.D., Executive VP & Chief Legal Officer
Comp: $1.11M
Ms. Shiva G. Fritsch
Chief Communications & People Officer
Dr. Laura A. Coruzzi J.D. (Age 69)
Ph.D., Executive Vice President of Intellectual Property
Dr. Ram Palanki Pharm.D. (Age 47)
Executive VP of Commercial Strategy & Operations
Dr. Stephen Yoo M.D. (Age 45)
Consultant
Comp: $573.71k

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

RGNX Stock Analysis - Frequently Asked Questions

Should I buy or sell REGENXBIO stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RGNX shares.
View RGNX analyst ratings or view top-rated stocks.
What is REGENXBIO's stock price target for 2024?: 8 brokers have issued twelve-month price objectives for REGENXBIO's shares. Their RGNX share price targets range from $14.00 to $55.00. On average, they anticipate the company's stock price to reach $31.13 in the next twelve months. This suggests a possible upside of 59.5% from the stock's current price.
View analysts price targets for RGNX or view top-rated stocks among Wall Street analysts.
How have RGNX shares performed in 2023?: REGENXBIO's stock was trading at $22.68 at the start of the year. Since then, RGNX shares have decreased by 13.9% and is now trading at $19.52.
View the best growth stocks for 2023 here.
When is REGENXBIO's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our RGNX earnings forecast.
How were REGENXBIO's earnings last quarter?: REGENXBIO Inc. (NASDAQ:RGNX) posted its earnings results on Wednesday, November, 8th. The biotechnology company reported ($1.41) EPS for the quarter, topping analysts' consensus estimates of ($1.44) by $0.03. The biotechnology company had revenue of $28.90 million for the quarter, compared to analyst estimates of $26.14 million. REGENXBIO had a negative trailing twelve-month return on equity of 59.54% and a negative net margin of 262.18%. The firm's revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter last year, the company earned ($1.75) EPS.
What ETFs hold REGENXBIO's stock?: ETFs with the largest weight of REGENXBIO (NASDAQ:RGNX) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What is Ken Mills' approval rating as REGENXBIO's CEO?: 3 employees have rated REGENXBIO Chief Executive Officer Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among the company's employees.
What other stocks do shareholders of REGENXBIO own?: Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Block (SQ).
Who are REGENXBIO's major shareholders?: REGENXBIO's stock is owned by many different retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (8.33%), Redmile Group LLC (5.85%), Jacobs Levy Equity Management Inc. (1.28%), Northern Trust Corp (0.98%), Bank of New York Mellon Corp (0.82%) and Charles Schwab Investment Management Inc. (0.74%). Insiders that own company stock include Allan M Fox, Curran Simpson, Kenneth T Mills, Kenneth T Mills, Patrick J Christmas, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust.
View institutional ownership trends.
How do I buy shares of REGENXBIO?: Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:RGNX) was last updated on 12/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial